Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort
Introduction Migrants living with HIV often face high mobility, vulnerability and limited baseline information on HIV-1 genotype or treatment history. We aimed to assess the effectiveness and persistence of long-acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) among migrants in Spain.Met...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2026 |
| País: | España |
| Recursos: | Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| Repositorio: | r-FISABIO. Repositorio Institucional de Producción Científica |
| OAI Identifier: | oai:dnet:r-fisabio___::b7161a878cca7b9345e2407ac217d5e7 |
| Acesso em linha: | https://fisabio.portalinvestigacion.com/publicaciones/21177 |
| Access Level: | acceso abierto |
| Palavra-chave: | antiretroviral treatment cabotegravir effectiveness health access HIV long-acting migration persistence |
| id |
ES_6b04ee75fc4355f474aa9da3e1f79ee0 |
|---|---|
| oai_identifier_str |
oai:dnet:r-fisabio___::b7161a878cca7b9345e2407ac217d5e7 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY CohortLlenas-García, JRueda, MDAHernaiz, RCTomé, RPPardo, OBMatarranz, MTorralba, MPuerto, MJGRodríguez, AVera, MPConde, ISMoral, SDCabello-Ubeda, ASan Francisco, CNCuéllar, KAAragón, MPGarcía, MATiraboschi, JAlvarez, RMMVivancos, MJHernández, CMMorell, EBCabello-Clotet, NAmado, LEMPérez, LGSepúlveda, MAValls, MRAGuirao, AJSFanciulli, CEscrig, CPasos, EMFLucas-Dato, ATorras, SGTenorio, CHEstébanez, MMuelas-Fernandez, MGarcía, JELCalviño, ACDíaz, MEPMontes, CMGarcía, VAde las Revillas, FAPardavila, HPPadilla, SJiménez, MAGAlonso, LAVicente, NRGallo, PNBMagadan, RCdel Alamo, MMurciano, MVEToquero, AJPalacios, AROlmos, MCNavarro, MDGSanz, JGainzarain, JCSanz, MMde la Calle, BBenéitez, OLFTroya, JBuzón-Martín, Lantiretroviral treatmentcabotegravireffectivenesshealth accessHIVlong-actingmigrationpersistenceIntroduction Migrants living with HIV often face high mobility, vulnerability and limited baseline information on HIV-1 genotype or treatment history. We aimed to assess the effectiveness and persistence of long-acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) among migrants in Spain.Methods This multicentre cohort study across 58 Spanish hospitals included virologically suppressed adults switching to CAB+RPV LAI before January 2025. Data collection started in June 2023. Baseline characteristics and outcomes were compared by migrant status, and multivariate Cox proportional hazards regression models were fitted to assess factors associated with virological failure (VF) and discontinuation. Propensity score matching (PSM) by gender, age, known genotype and prior VF was employed to control for confounding.Results Of 3135 participants, 951 (30.3%) were migrants, predominantly from Latin America. Median follow-up was 13.8 months (interquartile range 8.91-19.1). VF occurred in 0.9% of migrants versus 0.5% of Spanish-born individuals (odds ratio 1.89, 95% confidence interval [CI] 0.69-5.03; p = 0.22). In adjusted models, migrant status showed a non-significant trend towards higher VF (adjusted hazard ratio [aHR] 2.16, 95% CI 0.89-5.22; p = 0.079). At 12 months, 95.8% of migrants (461/481) persisted on LAI CAB+RPV treatment versus 98.3% of Spanish-born individuals (1348/1372) (p = 0.005). Discontinuation due to any adverse event was more frequent in migrants (3.3% vs. 1.8%). Migrant status was significantly associated with discontinuation due to both local (aHR 2.63, 95% CI 1.33-5.26; p = 0.005) and systemic adverse events (aHR 3.33, 95% CI 1.45-7.69, p = 0.005).Conclusions Nearly one-third of participants switching to LAI CAB+RPV were migrants. While VF was rare overall, migrants had a significantly higher risk of treatment discontinuation, partly driven by adverse events. These findings highlight the need for closer monitoring and tailored strategies to optimize persistence with LAI regimens in migrant populations.JOHN WILEY & SONS LTD2026info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/21177Journal of the International AIDS SocietyISSN: 17582652reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:dnet:r-fisabio___::b7161a878cca7b9345e2407ac217d5e72026-06-11T12:45:17Z |
| dc.title.none.fl_str_mv |
Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort |
| title |
Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort |
| spellingShingle |
Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort Llenas-García, J antiretroviral treatment cabotegravir effectiveness health access HIV long-acting migration persistence |
| title_short |
Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort |
| title_full |
Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort |
| title_fullStr |
Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort |
| title_full_unstemmed |
Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort |
| title_sort |
Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort |
| dc.creator.none.fl_str_mv |
Llenas-García, J Rueda, MDA Hernaiz, RC Tomé, RP Pardo, OB Matarranz, M Torralba, M Puerto, MJG Rodríguez, A Vera, MP Conde, IS Moral, SD Cabello-Ubeda, A San Francisco, CN Cuéllar, KA Aragón, MP García, MA Tiraboschi, J Alvarez, RMM Vivancos, MJ Hernández, CM Morell, EB Cabello-Clotet, N Amado, LEM Pérez, LG Sepúlveda, MA Valls, MRA Guirao, AJS Fanciulli, C Escrig, C Pasos, EMF Lucas-Dato, A Torras, SG Tenorio, CH Estébanez, M Muelas-Fernandez, M García, JEL Calviño, AC Díaz, MEP Montes, CM García, VA de las Revillas, FA Pardavila, HP Padilla, S Jiménez, MAG Alonso, LA Vicente, NR Gallo, PNB Magadan, RC del Alamo, M Murciano, MVE Toquero, AJ Palacios, AR Olmos, MC Navarro, MDG Sanz, J Gainzarain, JC Sanz, MM de la Calle, B Benéitez, OLF Troya, J Buzón-Martín, L |
| author |
Llenas-García, J |
| author_facet |
Llenas-García, J Rueda, MDA Hernaiz, RC Tomé, RP Pardo, OB Matarranz, M Torralba, M Puerto, MJG Rodríguez, A Vera, MP Conde, IS Moral, SD Cabello-Ubeda, A San Francisco, CN Cuéllar, KA Aragón, MP García, MA Tiraboschi, J Alvarez, RMM Vivancos, MJ Hernández, CM Morell, EB Cabello-Clotet, N Amado, LEM Pérez, LG Sepúlveda, MA Valls, MRA Guirao, AJS Fanciulli, C Escrig, C Pasos, EMF Lucas-Dato, A Torras, SG Tenorio, CH Estébanez, M Muelas-Fernandez, M García, JEL Calviño, AC Díaz, MEP Montes, CM García, VA de las Revillas, FA Pardavila, HP Padilla, S Jiménez, MAG Alonso, LA Vicente, NR Gallo, PNB Magadan, RC del Alamo, M Murciano, MVE Toquero, AJ Palacios, AR Olmos, MC Navarro, MDG Sanz, J Gainzarain, JC Sanz, MM de la Calle, B Benéitez, OLF Troya, J Buzón-Martín, L |
| author_role |
author |
| author2 |
Rueda, MDA Hernaiz, RC Tomé, RP Pardo, OB Matarranz, M Torralba, M Puerto, MJG Rodríguez, A Vera, MP Conde, IS Moral, SD Cabello-Ubeda, A San Francisco, CN Cuéllar, KA Aragón, MP García, MA Tiraboschi, J Alvarez, RMM Vivancos, MJ Hernández, CM Morell, EB Cabello-Clotet, N Amado, LEM Pérez, LG Sepúlveda, MA Valls, MRA Guirao, AJS Fanciulli, C Escrig, C Pasos, EMF Lucas-Dato, A Torras, SG Tenorio, CH Estébanez, M Muelas-Fernandez, M García, JEL Calviño, AC Díaz, MEP Montes, CM García, VA de las Revillas, FA Pardavila, HP Padilla, S Jiménez, MAG Alonso, LA Vicente, NR Gallo, PNB Magadan, RC del Alamo, M Murciano, MVE Toquero, AJ Palacios, AR Olmos, MC Navarro, MDG Sanz, J Gainzarain, JC Sanz, MM de la Calle, B Benéitez, OLF Troya, J Buzón-Martín, L |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
antiretroviral treatment cabotegravir effectiveness health access HIV long-acting migration persistence |
| topic |
antiretroviral treatment cabotegravir effectiveness health access HIV long-acting migration persistence |
| description |
Introduction Migrants living with HIV often face high mobility, vulnerability and limited baseline information on HIV-1 genotype or treatment history. We aimed to assess the effectiveness and persistence of long-acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) among migrants in Spain.Methods This multicentre cohort study across 58 Spanish hospitals included virologically suppressed adults switching to CAB+RPV LAI before January 2025. Data collection started in June 2023. Baseline characteristics and outcomes were compared by migrant status, and multivariate Cox proportional hazards regression models were fitted to assess factors associated with virological failure (VF) and discontinuation. Propensity score matching (PSM) by gender, age, known genotype and prior VF was employed to control for confounding.Results Of 3135 participants, 951 (30.3%) were migrants, predominantly from Latin America. Median follow-up was 13.8 months (interquartile range 8.91-19.1). VF occurred in 0.9% of migrants versus 0.5% of Spanish-born individuals (odds ratio 1.89, 95% confidence interval [CI] 0.69-5.03; p = 0.22). In adjusted models, migrant status showed a non-significant trend towards higher VF (adjusted hazard ratio [aHR] 2.16, 95% CI 0.89-5.22; p = 0.079). At 12 months, 95.8% of migrants (461/481) persisted on LAI CAB+RPV treatment versus 98.3% of Spanish-born individuals (1348/1372) (p = 0.005). Discontinuation due to any adverse event was more frequent in migrants (3.3% vs. 1.8%). Migrant status was significantly associated with discontinuation due to both local (aHR 2.63, 95% CI 1.33-5.26; p = 0.005) and systemic adverse events (aHR 3.33, 95% CI 1.45-7.69, p = 0.005).Conclusions Nearly one-third of participants switching to LAI CAB+RPV were migrants. While VF was rare overall, migrants had a significantly higher risk of treatment discontinuation, partly driven by adverse events. These findings highlight the need for closer monitoring and tailored strategies to optimize persistence with LAI regimens in migrant populations. |
| publishDate |
2026 |
| dc.date.none.fl_str_mv |
2026 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://fisabio.portalinvestigacion.com/publicaciones/21177 |
| url |
https://fisabio.portalinvestigacion.com/publicaciones/21177 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
JOHN WILEY & SONS LTD |
| publisher.none.fl_str_mv |
JOHN WILEY & SONS LTD |
| dc.source.none.fl_str_mv |
Journal of the International AIDS Society ISSN: 17582652 reponame:r-FISABIO. Repositorio Institucional de Producción Científica instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| instname_str |
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| reponame_str |
r-FISABIO. Repositorio Institucional de Producción Científica |
| collection |
r-FISABIO. Repositorio Institucional de Producción Científica |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869410154343038976 |
| score |
15.811543 |